Edward Nash
Stock Analyst at Canaccord Genuity
(4.29)
# 379
Out of 4,893 analysts
82
Total ratings
49.3%
Success rate
19.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Nash
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRNA Verona Pharma | Downgrades: Hold | $107 | $104.85 | +2.05% | 10 | Jul 9, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $394 → $420 | $314.64 | +33.49% | 9 | May 2, 2025 | |
| CLDX Celldex Therapeutics | Initiates: Buy | $64 | $22.68 | +182.19% | 1 | Apr 28, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $45 → $47 | $16.49 | +185.02% | 10 | Apr 10, 2025 | |
| CORT Corcept Therapeutics | Maintains: Buy | $130 → $142 | $72.01 | +97.19% | 7 | Apr 1, 2025 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $9 | $0.66 | +1,263.02% | 2 | Feb 26, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Hold | $4 | $1.40 | +185.71% | 2 | Feb 10, 2025 | |
| AKRO Akero Therapeutics | Maintains: Buy | $56 → $73 | $52.00 | +40.38% | 6 | Jan 28, 2025 | |
| APGE Apogee Therapeutics | Initiates: Buy | $89 | $38.57 | +130.75% | 1 | Nov 25, 2024 | |
| VTYX Ventyx Biosciences | Maintains: Buy | $15 → $14 | $2.84 | +392.96% | 6 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $8 | $1.36 | +488.24% | 3 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $20 | $3.38 | +491.72% | 2 | Apr 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $8 | $3.15 | +153.97% | 4 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $17 | $5.25 | +224.12% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $3 → $2 | $2.16 | -7.41% | 4 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $900 → $180 | $2.03 | +8,767.00% | 2 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $82 | $31.04 | +164.22% | 6 | Jun 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $120 → $80 | $2.72 | +2,841.18% | 3 | Sep 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $14.90 | +222.15% | 1 | May 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $650 | $5.85 | +11,011.11% | 1 | Nov 8, 2017 |
Verona Pharma
Jul 9, 2025
Downgrades: Hold
Price Target: $107
Current: $104.85
Upside: +2.05%
Madrigal Pharmaceuticals
May 2, 2025
Maintains: Buy
Price Target: $394 → $420
Current: $314.64
Upside: +33.49%
Celldex Therapeutics
Apr 28, 2025
Initiates: Buy
Price Target: $64
Current: $22.68
Upside: +182.19%
Travere Therapeutics
Apr 10, 2025
Maintains: Buy
Price Target: $45 → $47
Current: $16.49
Upside: +185.02%
Corcept Therapeutics
Apr 1, 2025
Maintains: Buy
Price Target: $130 → $142
Current: $72.01
Upside: +97.19%
Rani Therapeutics Holdings
Feb 26, 2025
Maintains: Buy
Price Target: $9
Current: $0.66
Upside: +1,263.02%
Pliant Therapeutics
Feb 10, 2025
Downgrades: Hold
Price Target: $4
Current: $1.40
Upside: +185.71%
Akero Therapeutics
Jan 28, 2025
Maintains: Buy
Price Target: $56 → $73
Current: $52.00
Upside: +40.38%
Apogee Therapeutics
Nov 25, 2024
Initiates: Buy
Price Target: $89
Current: $38.57
Upside: +130.75%
Ventyx Biosciences
Aug 12, 2024
Maintains: Buy
Price Target: $15 → $14
Current: $2.84
Upside: +392.96%
May 23, 2024
Maintains: Buy
Price Target: $6 → $8
Current: $1.36
Upside: +488.24%
Apr 8, 2024
Maintains: Buy
Price Target: $12 → $20
Current: $3.38
Upside: +491.72%
Jul 3, 2023
Assumes: Hold
Price Target: $8
Current: $3.15
Upside: +153.97%
May 19, 2023
Maintains: Buy
Price Target: $16 → $17
Current: $5.25
Upside: +224.12%
May 17, 2023
Maintains: Hold
Price Target: $3 → $2
Current: $2.16
Upside: -7.41%
Aug 8, 2022
Downgrades: Hold
Price Target: $900 → $180
Current: $2.03
Upside: +8,767.00%
Jun 19, 2020
Maintains: Buy
Price Target: $80 → $82
Current: $31.04
Upside: +164.22%
Sep 13, 2019
Maintains: Hold
Price Target: $120 → $80
Current: $2.72
Upside: +2,841.18%
May 24, 2018
Initiates: Buy
Price Target: $48
Current: $14.90
Upside: +222.15%
Nov 8, 2017
Initiates: Buy
Price Target: $650
Current: $5.85
Upside: +11,011.11%